Literature DB >> 29386373

Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: does age really matter?

Stefan O Ciurea1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29386373      PMCID： PMC5792261          DOI： 10.3324/haematol.2017.186346

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

2.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Authors:  Richard F Schlenk; Sabine Kayser; Lars Bullinger; Guido Kobbe; Jochen Casper; Mark Ringhoffer; Gerhard Held; Peter Brossart; Michael Lübbert; Helmut R Salih; Thomas Kindler; Heinz A Horst; Gerald Wulf; David Nachbaur; Katharina Götze; Alexander Lamparter; Peter Paschka; Verena I Gaidzik; Veronica Teleanu; Daniela Späth; Axel Benner; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2014-09-30       Impact factor: 22.113

5.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Authors:  Sameh Gaballa; Rima Saliba; Betul Oran; Jonathan E Brammer; Julianne Chen; Gabriela Rondon; Amin M Alousi; Partow Kebriaei; David Marin; Uday R Popat; Borje S Andersson; Elizabeth J Shpall; Elias Jabbour; Naval Daver; Michael Andreeff; Farhad Ravandi; Jorge Cortes; Keyur Patel; Richard E Champlin; Stefan O Ciurea
Journal:  Am J Hematol       Date:  2017-02-13       Impact factor: 10.047

7.  Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.

Authors:  Amy E DeZern; Anthony Sung; Sharon Kim; B Douglas Smith; Judith E Karp; Steven D Gore; Richard J Jones; Ephraim Fuchs; Leo Luznik; Michael McDevitt; Mark Levis
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-13       Impact factor: 5.742

8.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

9.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Authors:  Hubert Serve; Utz Krug; Ruth Wagner; M Cristina Sauerland; Achim Heinecke; Uta Brunnberg; Markus Schaich; Oliver Ottmann; Justus Duyster; Hannes Wandt; Thomas Fischer; Aristoteles Giagounidis; Andreas Neubauer; Albrecht Reichle; Walter Aulitzky; Richard Noppeney; Igor Blau; Volker Kunzmann; Reingard Stuhlmann; Alwin Krämer; Karl-Anton Kreuzer; Christian Brandts; Björn Steffen; Christian Thiede; Carsten Müller-Tidow; Gerhard Ehninger; Wolfgang E Berdel
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

10.  Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Authors:  Lori Muffly; Marcelo C Pasquini; Michael Martens; Ruta Brazauskas; Xiaochun Zhu; Kehinde Adekola; Mahmoud Aljurf; Karen K Ballen; Ashish Bajel; Frederic Baron; Minoo Battiwalla; Amer Beitinjaneh; Jean-Yves Cahn; Mathew Carabasi; Yi-Bin Chen; Saurabh Chhabra; Stefan Ciurea; Edward Copelan; Anita D'Souza; John Edwards; James Foran; Cesar O Freytes; Henry C Fung; Robert Peter Gale; Sergio Giralt; Shahrukh K Hashmi; Gerhard C Hildebrandt; Vincent Ho; Ann Jakubowski; Hillard Lazarus; Marlise R Luskin; Rodrigo Martino; Richard Maziarz; Philip McCarthy; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Attaphol Pawarode; Edward Peres; Andrew R Rezvani; David Rizzieri; Bipin N Savani; Harry C Schouten; Mitchell Sabloff; Matthew Seftel; Sachiko Seo; Mohamed L Sorror; Jeff Szer; Baldeep M Wirk; William A Wood; Andrew Artz
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113
View more
  1 in total

1.  Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification.

Authors:  Tong-Yoon Kim; Silvia Park; Daehun Kwag; Jong-Hyuk Lee; Joonyeop Lee; Gi-June Min; Sung-Soo Park; Young-Woo Jeon; Seung-Hawn Shin; Seung-Ah Yahng; Jae-Ho Yoon; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Jong-Wook Lee; Hee-Je Kim
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.